Regeneron Pharmaceuticals, Inc.’s Stock Price Drops to $527.78, Down by 3.63%: A Deep Dive into REGN’s Performance

Regeneron Pharmaceuticals, Inc. (REGN)

527.78 USD -19.89 (-3.63%) Volume: 1.43M

Regeneron Pharmaceuticals, Inc.’s stock price stands at 527.78 USD, experiencing a decrease of -3.63% in the most recent trading session and a negative Year-to-Date (YTD) performance of -25.91%, with a trading volume of 1.43M.

Latest developments on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. (REGN) saw its stock underperform on Friday compared to competitors, despite being among billionaire Mario Gabelli’s large-cap stock picks with significant upside potential. Investment analysts have recently updated their ratings for REGN, while Capitolis Liquid Global Markets LLC acquired 49,000 shares of the company. However, Jim Cramer noted that the numbers for Regeneron Pharmaceuticals came up a little short, impacting the stock price movement. Despite this, Cutter Capital Management LP still holds REGN as its largest position. With daily progress showing a 0.43 gain, closing at 560.93, the market continues to watch the pharmaceutical company closely.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma